News & Events

The Key Technology Of Biocytogen’s Fully Human Antibody Renmab Platform Has Been Granted A Chinese Patent

Beijing, China, July 11, 2023 - Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) announced its independently developed key technology of RenMabTM platform has been…

Read more
Biocytogen Pharmaceuticals Enters Into License Agreement With Pheon Therapeutics

Exclusive License Agreement for an Oncological Target Antibody to Develop Best-In-Class ADC Beijing, China and London, UK, July 5, 2023 - Biocytogen Pharmaceuticals (Beijing) Co.,…

Read more
Webinar: Bispecific Antibody-Drug Conjugates (BsADCs): An Emerging, Promising Anti-Cancer Therapeutic Modality With Improved Efficacy And Safety

  Our webinar “Bispecific Antibody-Drug Conjugates (BsADCs): An Emerging, Promising Anti-Cancer Therapeutic Modality With Improved Efficacy And Safety" was live at 12:00 PM EDT on July…

Read more
Join us at Chinese American Diabetes Association 2023 Annual Meeting: June 20-23

Join us at the Chinese American Diabetes Association 2023 Annual Meeting in San Diego, CA from June 20-23! Learn more about our custom model generation…

Read more
Visit Our Bispecific ADC Poster at IO Summit Europe 2023!

Visit Our Bispecific ADC Poster at IO Summit Europe 2023! Biocytogen’s antibody Business Development & Licensing team is excited to attend the upcoming Immuno-Oncology Summit…

Read more
Join us at the 6th Annual Next-Gen Immuno-Oncology: June 22-23

Join us in our presentation and meet with our team if you are also attending 6th Annual Next-Gen Immuno-Oncology from June 22-23 in Boston! Learn…

Read more
Webinar: Generating Fully Human Antibodies and Antibody-based Therapeutics with RenMab, RenLite & RenNano Mice

  Our webinar “Generating Fully Human Antibodies and Antibody-based Therapeutics with RenMabTM, RenLiteⓇ & RenNanoTM Mice" was live at 1:00 PM EDT on June 20th, 2023. …

Read more
Biocytogen Opens San Francisco Office to Accelerate Globalization

Beijing, China and San Francisco, CA, May 31, 2023 - Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) has announced the opening of a new…

Read more
Biocytogen to Present Pipeline Assets and R&D Progress at BIO International Convention, June 5-8, 2023

Biocytogen’s antibody BD and licensing (BDL) team will be delivering an oral presentation on Monday, June 5th at the 2023 BIO International Convention in Boston,…

Read more
Meet Biocytogen’s APAC Business Development Team at 70th JALAS 2023!

Biocytogen’s Asia-Pacific business development team is pleased to exhibit at the 70th Japanese Association for Laboratory Animal Science (JALAS) annual meeting from May 24-26, 2023…

Read more
Back to top